By Lana Pine | Published on December 17, 2025 4 min read A large real-world study published in Neurology found that people with Type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists had a lower risk of developing epilepsy than those taking dipeptidyl peptidase-4 (DPP-4) inhibitors
The literature on this class of medications primarily highlights that they are generally well-tolerated with a low incidence of significant neurological adverse events
If feasible, this approach may be useful for establishing meaningful change thresholds for clinical care and research, including clinical trials
To remove CTAB, the sediment obtained was washed 3 times in a mixture of ethanol and 1 M hydrochloric acid with a ratio of 1:10 to remove the surfactant
For mild symptoms , you can typically continue your GLP-1 medication while focusing on aggressive hydration and rest
Each injection contains a carefully crafted blend of nutrients and vitamins for a variety of client concerns
&srotate=0)
